NCT03656575View on ClinicalTrials.gov

Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

April 20, 2019

Study Completion Date

April 20, 2019

Conditions
Osteoarthritis
Interventions
BIOLOGICAL

synovial fluid biomarker concentrations

Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03656575 - Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin | Biotech Hunter | Biotech Hunter